Aldeyra presents noninfectious anterior uveitis Phase 2 clinical trial data
Aldeyra Therapeutics presented new statistical analyses of the results of a randomized, multi-center, investigator-masked, comparator-controlled, parallel-group Phase 2 clinical trial of topical ocular reproxalap (formerly known as ADX-102), a first-in-class aldehyde sequestering agent, to the American Uveitis Society held at the American Academy of Ophthalmology 2017 Annual Meeting. The results of the analyses demonstrated formal statistical non-inferiority (p=0.036 after two weeks of therapy, p=0.048 after four weeks of therapy) of 0.5% reproxalap ophthalmic solution to Pred Forte, a topical ocular corticosteroid, in reducing anterior chamber inflammatory cell count, the standard noninfectious anterior uveitis clinical endpoint. The combination of reproxalap and low-frequency (twice-daily) Pred Forte administration was also statistically non-inferior to Pred Forte monotherapy (four-times-daily). Dr. John Sheppard, an internationally recognized expert in ocular inflammation, gave the presentation, which is available on the investor relations page of the Aldeyra Therapeutics.